PMID- 31033004
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20210109
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 33
IP  - 6
DP  - 2019 Jul
TI  - Decreased expression of FcgammaRII in active Graves' disease patients.
PG  - e22904
LID - 10.1002/jcla.22904 [doi]
LID - e22904
AB  - BACKGROUND: Graves' disease (GD) is a common autoimmune disease characterized by 
      genetic and environmental factors. Fcgamma receptors (FcgammaRs) are involved in several 
      autoimmune disorders through recognizing immunoglobulin (Ig) G antibodies and 
      mediating immune response. The study on the expression of FcgammaRs in GD patients is 
      scarce. The purpose of this study was to evaluate the expression of three 
      different types of FcgammaRs in patients with active and remissive GD. METHODS: Blood 
      samples of patients and healthy subjects were collected to analyze the percentage 
      of FcgammaRI (CD64), FcgammaRII (CD32), and FcgammaRIII (CD16) on peripheral blood 
      mononuclear cells (PBMCs) and monocytes by flow cytometry and Western blotting. 
      CD32 isotypes were also examined in cases and controls by real-time PCR. RESULTS: 
      The cell percentages expressed CD32 and protein expressions of CD32 on PBMCs, and 
      monocytes from patients with active GD were significantly reduced compared to 
      controls and patients with remissive GD. In particular, the expression of CD32B 
      on PBMC was also decreased in active GD patients. However, the cell percentages 
      expressed CD16 and CD64 from PBMCs and monocytes were comparable between three 
      groups. Besides, the percentages of CD14(+) CD32(+) cells were negatively 
      correlated with TRAb titers in active GD patients (r = -0.5825, P ＜ 0.001). 
      CONCLUSION: These results suggested that CD32 may act as a novel marker for 
      active GDs. The expression of monocytic CD32, in particular CD32B, in GD patients 
      might play a crucial role in maintaining FcgammaRs function and be a therapeutic 
      target in GD patients.
CI  - (c) 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley 
      Periodicals, Inc.
FAU - Lu, Xixuan
AU  - Lu X
AUID- ORCID: 0000-0002-1251-1217
AD  - Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning 
      Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of 
      China Medical University, Shenyang, China.
FAU - Peng, Shiqiao
AU  - Peng S
AD  - Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning 
      Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of 
      China Medical University, Shenyang, China.
FAU - Wang, Xinyi
AU  - Wang X
AD  - Department of Laboratory Medicine, The First Affiliated Hospital of China Medical 
      University, Shenyang, China.
FAU - Shan, Zhongyan
AU  - Shan Z
AD  - Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning 
      Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of 
      China Medical University, Shenyang, China.
FAU - Teng, Weiping
AU  - Teng W
AD  - Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning 
      Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of 
      China Medical University, Shenyang, China.
LA  - eng
GR  - LJQ2015115/Liaoning Excellent Talents in University/
GR  - YQ20170007/Excellent Youth Scientific program in China Medical University/
GR  - 81400777/Chinese National Natural Science Foundation/
GR  - 81570708/Chinese National Natural Science Foundation/
GR  - 201501042/Doctoral Scientific Research start-up Foundation of Liaoning Province/
GR  - 201601132/Doctoral Scientific Research start-up Foundation of Liaoning Province/
PT  - Journal Article
DEP - 20190429
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Biomarkers)
RN  - 0 (CD14 protein, human)
RN  - 0 (FCGR3B protein, human)
RN  - 0 (Fc gamma receptor IIB)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Female
MH  - GPI-Linked Proteins/blood
MH  - Graves Disease/*blood/immunology
MH  - Humans
MH  - Leukocytes, Mononuclear/immunology/metabolism
MH  - Lipopolysaccharide Receptors/metabolism
MH  - Male
MH  - Monocytes/immunology/metabolism
MH  - Receptors, IgG/*blood/genetics
PMC - PMC6642309
OTO - NOTNLM
OT  - CD32B
OT  - FcgammaR
OT  - FcgammaRII
OT  - Graves' disease
OT  - autoimmunity
EDAT- 2019/04/30 06:00
MHDA- 2020/01/07 06:00
PMCR- 2019/04/29
CRDT- 2019/04/30 06:00
PHST- 2019/01/17 00:00 [received]
PHST- 2019/03/27 00:00 [revised]
PHST- 2019/03/28 00:00 [accepted]
PHST- 2019/04/30 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2019/04/30 06:00 [entrez]
PHST- 2019/04/29 00:00 [pmc-release]
AID - JCLA22904 [pii]
AID - 10.1002/jcla.22904 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2019 Jul;33(6):e22904. doi: 10.1002/jcla.22904. Epub 2019 Apr 
      29.